India to Mexico: Acetaminophen Export Trade Route

To import finished pharmaceutical formulations containing Acetaminophen into Mexico, the following approvals and registrations are necessary:

• Sanitary Registration: All pharmaceutical products must obtain a sanitary registration from COFEPRIS before importation. This involves submitting a comprehensive dossier that includes detailed information about the product's composition, manufacturing process, quality control measures, and clinical data supporting its safety and efficacy.

• Dossier Format: The submission should follow the Common Technical Document (CTD) format, which standardizes the presentation of data for regulatory submissions.

• Approval Timelines: The approval process can vary in duration. While specific timelines are not publicly disclosed, applicants should anticipate a period of several months for COFEPRIS to review and approve the submission.

• Product Registration Fees: COFEPRIS charges fees for the evaluation and registration of pharmaceutical products. The exact fees depend on the type of product and the complexity of the evaluation.

• GMP Inspection Requirements: COFEPRIS mandates that manufacturing facilities comply with Good Manufacturing Practices (GMP). For foreign manufacturers, COFEPRIS may require a GMP certificate issued by a recognized regulatory authority or conduct its own inspection to verify compliance.

Indian exporters of Acetaminophen formulations must meet the following GMP certifications to supply products to Mexico:

• GMP Certification: Manufacturing facilities must possess a GMP certificate issued by a recognized regulatory authority. COFEPRIS recognizes GMP certificates from authorities that are members of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) or listed as World Health Organization Listed Authorities (WLAs).

• Approved Indian Facilities: As of November 2023, Shilpa Pharma Lifesciences Limited's API manufacturing facility in Raichur, Karnataka, underwent a successful GMP inspection by COFEPRIS and was issued a GMP certificate.

• Recent Inspections and Regulatory Actions: COFEPRIS conducts inspections of foreign manufacturing facilities to ensure compliance with GMP standards. While specific details of recent inspections or regulatory actions against Indian pharmaceutical companies are not publicly disclosed, it is imperative for exporters to maintain compliance with GMP standards to avoid potential regulatory actions.

In the past 18 months, several regulatory changes have impacted Indian pharmaceutical exports to Mexico:

• March 20, 2025: COFEPRIS published guidelines defining the requirements for Certificates of Good Manufacturing Practices (GMP) or equivalent documents necessary for sanitary registrations, renewals, and modifications. These guidelines specify the characteristics that GMP certificates must meet and recognize equivalent documents from certain National Regulatory Authorities (NRAs).

• April 17, 2025: COFEPRIS finalized the Good Manufacturing Practices Standard, NOM-241-SSA1-2025, for medical device manufacturers. While this standard primarily targets medical devices, it reflects COFEPRIS's ongoing efforts to enhance regulatory frameworks, which may indirectly influence pharmaceutical regulations.

These developments underscore COFEPRIS's commitment to aligning with international standards and enhancing the regulatory environment for pharmaceutical imports.

In 2025, the analgesics market in Mexico is projected to generate revenue of approximately $305.5 million USD, with an anticipated annual growth rate of 4.01% from 2025 to 2030. Acetaminophen, a widely used analgesic, contributes significantly to this market. The demand for acetaminophen formulations is driven by factors such as the high prevalence of chronic pain conditions, increasing consumer preference for over-the-counter pain relief medications, and a growing awareness of self-medication practices. While Mexico has domestic pharmaceutical manufacturing capabilities, the country also relies on imports to meet the demand for acetaminophen formulations. In 2024, Mexico imported acetaminophen formulations from various countries, including India, Costa Rica, China, and the United States.

Pharmaceutical products classified under HS code 30049069, including finished acetaminophen formulations, are subject to a 0% MFN import duty rate in Mexico. Additionally, Mexico applies a 16% Value Added Tax (VAT) to most sales and imports, including pharmaceuticals. There is no Free Trade Agreement (FTA) between India and Mexico that affects pharmaceutical tariffs. As of March 2026, there are no anti-dumping duties imposed on acetaminophen formulations imported into Mexico.

India is a significant supplier of acetaminophen formulations to Mexico, with exports totaling $5.5 million USD, accounting for 2.4% of India's total acetaminophen formulation exports. Other major countries supplying acetaminophen formulations to Mexico include Costa Rica, China, and the United States. India's competitive pricing and established pharmaceutical manufacturing capabilities contribute to its strong position in the Mexican market. While specific pricing comparisons between India and competitors like China and European Union manufacturers are not readily available, India's cost-effective production processes and economies of scale often result in competitive pricing for its pharmaceutical exports.

India is a global leader in generic pharmaceutical production, accounting for approximately 20% of the global generics trade. (zipdo.co) The country's pharmaceutical manufacturing sector boasts an annual capacity exceeding 70 billion dosage units, encompassing a wide range of finished dosage forms, including tablets, capsules, and syrups. (zipdo.co)

As of 2024, India operates 752 FDA-approved generic medicine facilities, surpassing the United States, and 2,050 WHO-GMP certified facilities. This extensive infrastructure ensures the production of high-quality Acetaminophen formulations that meet stringent international standards.

The cost structure of Indian pharmaceutical manufacturing is notably competitive, with production costs approximately 30% to 35% lower than those in the U.S. and Europe. This cost advantage is attributed to lower labor expenses, efficient cost-control measures, and the accelerated adoption of digital technologies.

In the third quarter of 2025, the price per metric ton of Paracetamol (Acetaminophen) was as follows:

• India: $2,911
• China: $3,415
• Germany: $3,496
• USA: $3,573
• France: $3,787

These figures highlight India's cost competitiveness in producing Acetaminophen formulations.

Regarding quality perception, Indian pharmaceutical manufacturers have made significant strides in compliance and quality assurance. Between 2013 and 2024, the number of "Official Action Indicated" notices issued by the FDA to Indian firms decreased by 50%, reflecting improved regulatory compliance. Additionally, India's pharmaceutical facilities have achieved over 99.9% right-first-time performance, ensuring consistent product quality.

In Mexico, Indian Acetaminophen formulations are well-accepted, with top buyers including TO ($2.0M), TO HELM DE ($1.7M), and CHEMO S A DE C V R F C CEM140616PV7 ($0.8M). This indicates a strong presence and trust in Indian pharmaceutical products within the Mexican market.

India's pharmaceutical industry has demonstrated robust supply reliability, supported by substantial manufacturing capacities. For instance, Granules India Limited, a leading producer of Acetaminophen formulations, has an annual production capacity exceeding 25,000 metric tons across three WHO-GMP facilities.

The packaging and cold chain capabilities for formulations are well-established, ensuring the integrity of products during transit. Indian manufacturers have invested in advanced infrastructure to meet global standards, including the adoption of Fourth Industrial Revolution (4IR) technologies, positioning India as a leader in pharmaceutical manufacturing innovation.

There have been no significant supply disruptions reported in recent years, indicating a stable supply chain. The regulatory compliance track record of Indian manufacturers has improved markedly, with a 50% reduction in FDA "Official Action Indicated" outcomes over the last decade.

Top Indian formulation manufacturers continue to expand their capacities. For example, Farmson Pharmaceutical Gujarat Pvt Ltd has invested $45 million in capacity expansions since 2020, enhancing their ability to meet global demand.

For Mexican buyers sourcing Acetaminophen formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among suppliers. It's advisable to negotiate terms that align with your demand forecasts and storage capabilities.

• Payment Terms: Common payment terms in India-Mexico pharmaceutical trade include Letters of Credit (LC) and advance payments. Establish clear payment agreements to maintain smooth transactions.

• Supplier Qualification Process: Conduct thorough due diligence, including audits of manufacturing facilities, verification of regulatory approvals (such as FDA and WHO-GMP certifications), and assessment of quality control systems.

• Regulatory Compliance: Ensure that the selected suppliers comply with both Indian and Mexican regulatory requirements to facilitate seamless importation and distribution.

By implementing these strategies, Mexican buyers can effectively source high-quality Acetaminophen formulations from India, leveraging the country's manufacturing advantages and cost efficiencies.

Cost Estimates and Timeline:

• Audit Visits to India:
• Plan for a 5-day on-site audit, including travel time.
• Estimated cost: $10,000–$15,000 USD, covering auditor fees, travel, and accommodation.

• Remote Monitoring:
• Ongoing costs for virtual audits and document reviews: $2,000–$5,000 USD annually.

By adhering to this comprehensive framework, Mexican pharmaceutical companies can ensure the selection of reliable Indian suppliers for acetaminophen formulations, maintaining high standards of product quality and regulatory compliance.